{"id":"efgartigimod-ph20-sc","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Efgartigimod competitively binds to FcRn, a receptor responsible for recycling and maintaining IgG levels in circulation. By blocking this interaction, the drug accelerates IgG catabolism and reduces pathogenic autoantibody levels. The PH20 subcutaneous formulation uses hyaluronidase to enable subcutaneous administration with improved bioavailability.","oneSentence":"Efgartigimod is an IgG Fc fragment that binds to the neonatal Fc receptor (FcRn) to reduce circulating immunoglobulin levels, particularly IgG antibodies.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:29:28.948Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Generalized myasthenia gravis (gMG)"},{"name":"Chronic inflammatory demyelinating polyneuropathy (CIDP)"}]},"trialDetails":[{"nctId":"NCT04777734","phase":"","title":"Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"AVAILABLE","sponsor":"argenx","startDate":"","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), CIDP","enrollment":""},{"nctId":"NCT06503731","phase":"PHASE2","title":"A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)","status":"RECRUITING","sponsor":"argenx","startDate":"2024-08-30","conditions":"Antibody-mediated Rejection","enrollment":30},{"nctId":"NCT06684847","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome","status":"RECRUITING","sponsor":"argenx","startDate":"2025-01-15","conditions":"Primary Sjogrens Disease","enrollment":580},{"nctId":"NCT06307613","phase":"PHASE3","title":"A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease","status":"TERMINATED","sponsor":"argenx","startDate":"2024-03-27","conditions":"Thyroid Eye Disease","enrollment":102},{"nctId":"NCT06307626","phase":"PHASE3","title":"A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.","status":"TERMINATED","sponsor":"argenx","startDate":"2024-03-28","conditions":"Thyroid Eye Disease","enrollment":105},{"nctId":"NCT07264426","phase":"","title":"Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study","status":"RECRUITING","sponsor":"argenx","startDate":"2025-08-11","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)","enrollment":200},{"nctId":"NCT06655155","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis","status":"RECRUITING","sponsor":"argenx","startDate":"2024-11-11","conditions":"Systemic Sclerosis (SSc)","enrollment":81},{"nctId":"NCT05979441","phase":"PHASE3","title":"A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy","status":"ENROLLING_BY_INVITATION","sponsor":"argenx","startDate":"2023-09-12","conditions":"Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis","enrollment":240},{"nctId":"NCT06909214","phase":"PHASE4","title":"A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)","status":"RECRUITING","sponsor":"argenx","startDate":"2025-04-17","conditions":"New Onset Generalized Myasthenia Gravis (gMG)","enrollment":30},{"nctId":"NCT05681481","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid","status":"TERMINATED","sponsor":"argenx","startDate":"2023-03-22","conditions":"Bullous Pemphigoid","enrollment":64},{"nctId":"NCT06299748","phase":"","title":"A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.","status":"RECRUITING","sponsor":"argenx","startDate":"2023-11-30","conditions":"Myasthenia Gravis, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":279},{"nctId":"NCT06637072","phase":"PHASE4","title":"A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC","status":"ACTIVE_NOT_RECRUITING","sponsor":"argenx","startDate":"2024-12-10","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":23},{"nctId":"NCT05374590","phase":"PHASE2, PHASE3","title":"Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis","status":"ENROLLING_BY_INVITATION","sponsor":"argenx","startDate":"2022-08-18","conditions":"Generalized Myasthenia Gravis, gMG","enrollment":12},{"nctId":"NCT04818671","phase":"PHASE3","title":"Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis","status":"COMPLETED","sponsor":"argenx","startDate":"2021-04-26","conditions":"Generalized Myasthenia Gravis","enrollment":184},{"nctId":"NCT04812925","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"argenx","startDate":"2021-11-17","conditions":"Primary Immune Thrombocytopenia","enrollment":173},{"nctId":"NCT06558279","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis","status":"ACTIVE_NOT_RECRUITING","sponsor":"argenx","startDate":"2024-09-18","conditions":"Myasthenia Gravis, Ocular","enrollment":141},{"nctId":"NCT06392386","phase":"PHASE2, PHASE3","title":"A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis","status":"RECRUITING","sponsor":"argenx","startDate":"2024-06-28","conditions":"Generalized Myasthenia Gravis","enrollment":12},{"nctId":"NCT05267600","phase":"PHASE2, PHASE3","title":"A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid","status":"COMPLETED","sponsor":"argenx","startDate":"2022-06-09","conditions":"Bullous Pemphigoid","enrollment":98},{"nctId":"NCT05523167","phase":"PHASE2, PHASE3","title":"A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"argenx","startDate":"2022-10-12","conditions":"Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis","enrollment":265},{"nctId":"NCT04280718","phase":"PHASE2","title":"A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)","status":"ACTIVE_NOT_RECRUITING","sponsor":"argenx","startDate":"2020-09-18","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","enrollment":229},{"nctId":"NCT04598477","phase":"PHASE3","title":"A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)","status":"TERMINATED","sponsor":"argenx","startDate":"2021-07-15","conditions":"Pemphigus Vulgaris, Pemphigus Foliaceus","enrollment":183},{"nctId":"NCT04687072","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia","status":"COMPLETED","sponsor":"argenx","startDate":"2020-12-16","conditions":"Primary Immune Thrombocytopenia","enrollment":207},{"nctId":"NCT04598451","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)","status":"COMPLETED","sponsor":"argenx","startDate":"2020-12-01","conditions":"Pemphigus Vulgaris, Pemphigus Foliaceus","enrollment":222},{"nctId":"NCT04281472","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)","status":"COMPLETED","sponsor":"argenx","startDate":"2020-04-15","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","enrollment":322},{"nctId":"NCT05817435","phase":"PHASE1","title":"A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults","status":"COMPLETED","sponsor":"argenx","startDate":"2023-03-13","conditions":"Bioequivalence","enrollment":120},{"nctId":"NCT04735432","phase":"PHASE3","title":"Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis","status":"COMPLETED","sponsor":"argenx","startDate":"2021-02-05","conditions":"Generalized Myasthenia Gravis","enrollment":110},{"nctId":"NCT04564066","phase":"PHASE1","title":"A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers","status":"COMPLETED","sponsor":"argenx","startDate":"2020-08-18","conditions":"Healthy Volunteers","enrollment":54},{"nctId":"NCT04073589","phase":"PHASE1","title":"Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects","status":"COMPLETED","sponsor":"argenx","startDate":"2019-07-17","conditions":"Healthy Volunteers","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ARGX-113 PH20 SC","ARGX-113"],"phase":"marketed","status":"active","brandName":"Efgartigimod PH20 SC","genericName":"Efgartigimod PH20 SC","companyName":"argenx","companyId":"argenx","modality":"Biologic","firstApprovalDate":"","aiSummary":"Efgartigimod PH20 SC is a protein-based antagonist that targets the IgG receptor FcRn large subunit p51. It is being studied in clinical trials for various conditions, including Thyroid Eye Disease, Chronic Inflammatory Demyelinating Polyneuropathy, and Generalized Myasthenia Gravis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}